Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of Apixaban and Atenolol
NCT02262533Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2007
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Apixaban and Atenolol plasma concentration. Started Jun 2007; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02262533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262533.